SLC5A2 and type 2 diabetes mellitus: Chan et al. reported that SGLT2 inhibitors were associated with a lower risk of new-onset AF in patients with T2D compared with DPP4 inhibitors (HR, 0.90; 95% CI, 0.84–0.96) in samples from Taiwan (Chan et al., 2022).